Translate page

iCMLf

Alliance

    Perspectives from Professor Jorge Cortes, MD

    MD Anderson Cancer Center
    University of Texas, Houston, USA

    • Different aspects on treatment discontinuation including 2nd treatment discontinuation and QoL assessment
    • Presentation of a new tyrosine kinase inhibitor
    • Generics making it into practice
    • Predictive markers and their impact on patients outcome
    • Considerations for treatment discontinuation in clinical practice including AE management


    {rscomments off}